From Medscape Oncology

Coverage from the

Genitourinary Cancers Symposium (GUCS) 2022

February 17 - 19, 2022; San Francisco, CA and Virtual/Online

February 17 - 19, 2022 San Francisco, CA and Virtual/Online

GUCS 2022 Neoadjuvant Chemo New SOC Option in Urothelial Carcinoma Neoadjuvant chemotherapy in the high-risk population demonstrated favorable pathologic responses, and was well tolerated.
Medscape Medical News, February 24, 2022
GUCS 2022 Twitter Storm Over 'Reprehensible Behavior' at Conference Podium A Twitter post calling out an exchange between a presenter and an attendee asking questions at the recent GUCS conference created a bit of a buzz.
Medscape Medical News, February 22, 2022
GUCS 2022 Adding Darolutamide: New SOC for Metastatic Prostate Cancer Darolutamide added onto ADT and docetaxel could be a new standard of care for men with metastatic hormone-sensitive prostate cancer.
Medscape Medical News, February 18, 2022

Conference News

GUCS 2022 Bladder Cancer Need Not Always Require Radical Cystectomy
Medscape Medical News, March 3, 2022
GUCS 2022 Testicular Cancer Deaths Rising Among Hispanic Men
Medscape Medical News, February 28, 2022
GUCS 2022 Neoadjuvant Chemo New SOC Option in Urothelial Carcinoma
Medscape Medical News, February 24, 2022
GUCS 2022 Genetic Score Predicts Lifetime Risk of Prostate Cancer Death
Medscape Medical News, February 23, 2022

GUCS 2022 Twitter Storm Over 'Reprehensible Behavior' at Conference Podium
Medscape Medical News, February 22, 2022
GUCS 2022 PARP Inhibitors: Improving Outcomes in Metastatic Prostate Cancer
Medscape Medical News, February 22, 2022
GUCS 2022 Adding Darolutamide: New SOC for Metastatic Prostate Cancer
Medscape Medical News, February 18, 2022

Medscape Oncology© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Popular News from GUCS 2021

Combo Shows 'Impressive' Survival Results in First-Line RCC The combination of lenvatinib and pembrolizumab outperformed sunitinib as first-line therapy for advanced clear-cell renal cell carcinoma (RCC) in the CLEAR trial.
Medscape Medical News, Feb 18, 2021
Drop in PSA Screening, Increase in Metastatic Prostate Cancers The incidence of metastatic prostate cancers at diagnosis increased as prostate-specific antigen (PSA) screenings across U.S. states decreased, registry data show.
Medscape Medical News, Feb 12, 2021
'Attractive' Option for Early Metastatic Seminoma For early-stage seminoma that metastasizes to one or two retroperitoneal lymph nodes, surgical excision is an "attractive" alternative, according to an investigator from the phase 2 SEMS trial.
Medscape Medical News, Feb 17, 2021

Previous Coverage